{
    "root": "6c96e35d-9099-e164-0960-353b01420f81",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Abiraterone Acetate",
    "value": "20250317",
    "ingredients": [
        {
            "name": "ABIRATERONE ACETATE",
            "code": "EM5OCB9YJ6"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "abiraterone acetate tablets indicated combination prednisone treatment patients metastatic castration-resistant prostate cancer ( crpc ) metastatic high-risk castration-sensitive prostate cancer ( cspc )",
    "contraindications": "­ metastatic castration-resistant prostate cancer : • abiraterone acetate tablets 1,000 mg orally daily prednisone 5 mg orally twice daily . ( 2.1 ) metastatic castration-sensitive prostate cancer : • abiraterone acetate tablets 1,000 mg orally daily prednisone 5 mg orally daily . ( 2.2 ) patients receiving abiraterone acetate tablets also receive gonadotropin-releasing hormone ( gnrh ) analog concurrently bilateral orchiectomy . abiraterone acetate tablets must taken single dose daily empty stomach . eat food 2 hours 1 hour taking abiraterone acetate tablets . tablets must swallowed whole water . crush chew tablets . ( 2.3 ) dose modification : • patients baseline moderate hepatic impairment ( child-pugh class b ) , reduce abiraterone acetate tablets starting dose 250 mg daily . ( 2.4 ) • patients develop hepatotoxicity treatment , hold abiraterone acetate tablets recovery . retreatment may initiated reduced dose . abiraterone acetate tablets discontinued patients develop severe hepatotoxicity . ( 2.4 )",
    "warningsAndPrecautions": "abiraterone acetate tablets usp , 250 mg white off-white , oval shaped , film coated tablets debossed “ 35 ” one side plain side . abiraterone acetate tablets usp , 250 mg available high-density polyethylene bottles 120 tablets also available unit dose package 30 ( 3 x 10 ) tablets . bottles 120 ndc 75907-224-04 unit dose package 30 ( 3 x 10 ) ndc 75907-224-31 abiraterone acetate tablets usp , 500 mg pinkish brown color , oval shaped , biconvex , film coated tablets , debossed `` 46 `` one side plain side free physical defects . abiraterone acetate tablets usp , 500 mg available high-density polyethylene bottles 60 tablets unit dose package 60 ( 6 x 10 ) tablets . bottles 60 ndc 75907-226-60 unit dose package 60 ( 6 x 10 ) ndc 75907-226-38. storage handling store 20°c 25°c ( 68°f 77°f ) ; excursions permitted range 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . keep reach children . based mechanism action , abiraterone acetate may harm developing fetus . women pregnant women may pregnant handle abiraterone acetate 250 mg tablets broken , crushed , damaged without protection , e.g . , gloves [ ( 8.1 ) ] .",
    "adverseReactions": "none .",
    "indications_original": "Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with\n                  \n                     \n                         Metastatic castration-resistant prostate cancer (CRPC) \n                     \n                     \n                        Metastatic high-risk castration-sensitive prostate cancer (CSPC)",
    "contraindications_original": "­ Metastatic castration-resistant prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally twice daily. ( 2.1 ) Metastatic castration-sensitive prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally once daily. ( 2.2 ) Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone acetate tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking abiraterone acetate tablets. The tablets must be swallowed whole with water. Do not crush or chew tablets.( 2.3) Dose Modification: • For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the abiraterone acetate tablets starting dose to 250 mg once daily. ( 2.4 ) • For patients who develop hepatotoxicity during treatment, hold abiraterone acetate tablets until recovery. Retreatment may be initiated at a reduced dose. Abiraterone acetate tablets should be discontinued if patients develop severe hepatotoxicity. ( 2.4 )",
    "warningsAndPrecautions_original": "Abiraterone acetate tablets USP, 250 mg are white to off-white, oval shaped, film coated tablets debossed with “35” on one side and plain on other side. \n                  Abiraterone acetate tablets USP, 250 mg are available in high-density polyethylene bottles of 120 tablets and also available in unit dose package of 30 (3 x 10) tablets. \n                  Bottles of 120 NDC 75907-224-04 \n                  Unit dose package of 30 (3 x 10) NDC 75907-224-31 \n                  Abiraterone acetate tablets USP, 500 mg are pinkish brown color, oval shaped, biconvex, film coated tablets, debossed with \"46\" on one side and plain other side and free from physical defects. Abiraterone acetate tablets USP, 500 mg are available in high-density polyethylene bottles of 60 tablets and unit dose package of 60 (6 x 10) tablets. \n                  Bottles of 60 NDC 75907-226-60 \n                  Unit dose package of 60 (6 x 10) NDC 75907-226-38.\n                  \n                     Storage and Handling \n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted in the range from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].  \n                  Keep out of reach of children.\n                  Based on its mechanism of action, abiraterone acetate may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle abiraterone acetate 250 mg tablets if broken, crushed, or damaged without protection, e.g., gloves [see Use in Specific Populations (\n                        8.1\n                     )].",
    "adverseReactions_original": "None."
}